MTOR and COVID-19: In contrast, in KT recipients with symptomatic COVID-19, the most frequently used approach was the suspension of the ADs or mTOR inhibitors, regardless the fact that both these IS drugs showed in vitro antiviral effects against some type of coronavirus.